Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Infinity Pharmaceuticals, Inc (NASDAQ: INFI) has announced that CEO Adelene Perkins will present at the 33rd Annual Virtual Healthcare Conference on November 22. This presentation will include a fireside chat with Piper's Senior Biotech Analyst, Ted Tenthoff, and will be available on Infinity's website. Additionally, management will hold 1-on-1 investor meetings from November 29 to December 2. Infinity is developing eganelisib, an oral immuno-oncology therapeutic targeting immune suppression in cancer.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that Adelene Perkins, Chief Executive Officer, will present at the upcoming Piper Sandler 33^rd Annual Virtual Healthcare Conference.

The presentation will be a fireside chat with Ted Tenthoff, Piper’s Senior Biotech Analyst, which will be available on the Company’s website beginning November 22^nd. Management will also be available for 1-on-1 meetings with investors during the conference which will take place November 29^th through December 2^nd.

Presentation details can be found below:

• 33^rd Annual Virtual Healthcare Conference
  Format: Presentation and 1-on-1 meetings
  Date and Time: Presentation available starting Monday, November 22^nd at 10:00am ET; 1-on-1 meetings November 29^th – December 2^nd

The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005998/en/

Investor Relations:

Irina Koffler

LifeSci Advisors, LLC

646-970-4681

ikoffler@lifesciadvisors.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

What is the date of Infinity Pharmaceuticals' presentation at the Piper Sandler 33rd Annual Virtual Healthcare Conference?

Infinity Pharmaceuticals will present on November 22, 2021.

Who will be presenting for Infinity Pharmaceuticals at the healthcare conference?

CEO Adelene Perkins will present at the conference.

When will the 1-on-1 investor meetings take place during the conference?

The 1-on-1 investor meetings will be held from November 29 to December 2, 2021.

What is eganelisib developed by Infinity Pharmaceuticals?

Eganelisib is a potentially first-in-class oral immuno-oncology therapeutic that reprograms macrophages to address immune suppression in cancer.

Where can I access the presentation and archived webcasts from Infinity Pharmaceuticals?

The presentations and archived webcasts can be accessed on Infinity's website, available for 30 days post-event.